Abstract
The prognostic influence of CA 125 regression between the time point before surgery and after two completed courses of chemotherapy was studied in 210 patients with advanced ovarian cancer, and was compared to other well established prognostic factors. CA 125 blood samples were collected preoperatively (CA 125 pre) and 3 months after surgery (CA 125 3 mo) (at the beginning of the 3rd cycle of chemotherapy). The parameter CA 125 regression defined as log10 (CA 125 3 mo/CA 125 pre) was used for statistical analysis. In a survival analysis using a Cox proportional hazards model, CA 125 regression (P = 0.0001), residual tumour (P = 0.0001), age (P = 0.0095) and grading (P = 0.044) were independent variables, whereas stage of disease, histology, ascites and type of surgery failed to retain significance. Using log10 (CA 125 3 mo/CA 125 pre) as simple covariate in a Cox model showed a hazard ratio of 1.70 (95% confidence interval 1.32–2.19, P = 0.0001). However, a detailed analysis of the interaction of time with the prognostic factor CA 125 regression on survival revealed a strong time-dependent effect with a hazard ratio of more than 6 immediately after two courses of chemotherapy, whereas within approximately 1 year the hazard ratio for the surviving patients dropped quickly to the neutral level of 1. In summary, CA 125 regression is an independent prognostic factor for survival of women with advanced ovarian cancer and allows an identification of a high-risk population among patients with advanced ovarian cancer. However, the discriminating power of serial CA 125 for long-term survival seems to be temporary and prediction of individual patients outcome is far less precise.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Atack, DB, Nisker, JA, Allen, HH, Tustanoff, ER & Levin, L (1986) CA 125 surveillance and second-look laparotomy in ovarian carcinoma. Am J Obstet Gynecol 154: 287–289
Averette, HE, Janicek, MF & Menck, HR (1996) The National Cancer Data Base report on ovarian cancer. American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 76: 1096–1103
Bast, RC Jr, Klug, TL, St John, E, Jenison, E, Niloff, JM, Lazarus, H, Berkowitz, RS, Laevitt, T, Griffiths, CT, Parker, L, Zurawski, VR Jr & Knapp, RC (1983) A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309: 883–887
Canney, PA, Moore, M, Wilkinson, PM & James, RD (1984) Ovarian cancer antigen CA-125: a prospective clinical assessment of its role as a tumour marker. Br J Cancer 50: 765–769
Cox, DR (1972) Regression models and life tables (with discussion). J Royal Statist Soc B 34: 187–220
Day, TG, Gallagher, HS & Rudledge, FN (1975) Epithelial carcinoma of the ovary: prognostic importance of histologic grade. J Natl Cancer Inst 42: 15–21
Fayers, PM, Rustin, G, Wood, R, Nelstrop, A, Leonard, RCF, Wilkinson, P, Cruickshank, D, McAllister, EJ, Redman, CWE, Parker, D, Scott, IV, Slevin, ML & Roulston, JE (1993) The prognostic value of serum CA 125 in patients with advanced ovarian carcinoma: an analysis of 573 patients by the Medical Research Council Working Party on Gynaecological Cancer. Int J Gynecol Cancer 3: 285–292
Hawkins, RE, Roberts, K, Wiltshaw, E, Mundy, J, Fryatt, IJ & McCready, VR (1989) The prognostic significance of the half-life of serum CA 125 in patients responding to chemotherapy for epithelial ovarian carcinoma. Br J Obstet Gynaecol 96: 1395–1399
Heinzl, H & Kaider, A (1997) Gaining more flexibility in Cox proportional hazards regression models with cubic spline functions. Comp Meth Prog Biomed 54: 201–208
Hess, KR (1994) Assessing time-by-covariate interactions in proportional hazards regression models using cubic spline functions. Statist Med 13: 1045–1062
Hunter, VJ, Daly, L, Helms, M, Soper, JT, Berchuck, A, Clarke-Pearson, DL & Bast, RC (1990) The prognostic significance of CA 125 half-life in patients with ovarian cancer who received primary chemotherapy after surgical cytoreduction. Am J Obstet Gynecol 163: 1164–1167
International Federation of Gynaecology Obstetrics (1987) Changes in definitions of clinical staging for carcinoma of the cervix and ovary. Am J Obstet Gynecol 156: 263–264
Kaplan, EL & Meier, P (1958) Nonparametric estimation from incomplete observations. J Am Statist Assoc 53: 457–481
Krag, KJ, Canellos, GP, Griffiths, CT, Knapp, RC, Parker, LM, Welch, WR, Klatt, M & Andersen, J (1989) Predictive factors for long term survival in patients with advanced ovarian cancer. Gynecol Oncol 34: 88–93
Lavin, PT, Knapp, RC, Malkasian, G, Whitney, CW & Berek, JC (1987) CA-125 for the monitoring of ovarian carcinoma during primary therapy. Obstet Gynecol 69: 223–227
Makar, AP, Kristensen, GB, Børmer, OP & Claes, GT (1993) Serum CA 125 level allows early identification of non-responders during induction chemotherapy. Gynecol Oncol 49: 73–79
Mogenson, O, Mogenson, B & Jakobsen, A (1990) Predictive value of CA 125 during early chemotherapy of advanced ovarian cancer. Gynecol Oncol 37: 44–46
Mogensen, O (1992) Prognostic value of CA 125 in advanced ovarian cancer. Gynecol Oncol 44: 207–212
Redman, CWE, Blackledge, Jr, Kelly, K, Powell, J, Buxton, EJ & Luesly, DM (1990) Early serum CA 125 response and outcome in epithelial ovarian cancer. Eur J Cancer 26: 593–596
Rustin, GJS, Gennings, JN, Nelstrop, AE, Covarrubias, H, Lambert, HE & Bagshawe, KD (1989) Use of CA-125 to predict survival of patients with ovarian carcinoma. J Clin Oncol 11: 1667–1671
Serov, SF, Scully, RE & Sorbin, LH (1973) Histological typing of ovarian tumors. In:International Histological Classification of Tumors, World Health Organization: Geneva, Switzerland 17–18
Sevelda, P, Schemper, M & Spona, J (1989) CA 125 as an independent prognostic factor for survival in patients with epithelial ovarian cancer. Am J Obstet Gynecol 161: 1213–1216
Swenerton, KD, Hislop, TG, Spinelli, J, LeRiche, JC, Yang, N & Boyes, DA (1985) Ovarian carcinoma: a multivariate analysis of prognostic factors. Obstet Gynecol 65: 264–269
Van der Burgh, MEL, Lammes, FB, Van Putten, WJL & Stotter, G (1988) Ovarian cancer: the prognostic value of the serum half-life of CA-125 during the induction of chemotherapy. Gynecol Oncol 30: 307–312
Yedema, CA, Kenemans, P, Voorhorst, F, Bon, G, Schijf, C, Beex, L, Verstraeten, A, Hilgers, J & Vermorken, J (1993a) CA 125 half-life in ovarian cancer: a multivariate survival analysis. Br J Cancer 67: 1361–1367
Yedema, CA, Kenemans, P, Thomas, CMG, Massuger, LFAG, Wobbes, TH, Verstraeten, AA, van Kamp, GJ & Hilgers, J (1993b) CA 125 serum levels in the early postoperative period do not reflect the outcome of cytoreductive surgery. Eur J Cancer 29: 966–971
Author information
Authors and Affiliations
Additional information
Correspondence to:C Peters-Engl
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Peters-Engl, C., Obermair, A., Heinzl, H. et al. CA 125 regression after two completed cycles of chemotherapy: lack of prediction for long-term survival in patients with advanced ovarian cancer. Br J Cancer 81, 662–666 (1999). https://doi.org/10.1038/sj.bjc.6690744
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.bjc.6690744
Keywords
This article is cited by
-
CA125-related tumor cell kinetics variables after chemotherapy in advanced ovarian cancer: a systematic review
Clinical and Translational Oncology (2016)
-
Can HE4 predict platinum response during first-line chemotherapy in ovarian cancer?
Tumor Biology (2014)
